Foghorn Therapeutics Inc. (NASDAQ:FHTX - Free Report) - Stock analysts at HC Wainwright lowered their Q3 2024 earnings per share estimates for Foghorn Therapeutics in a research note issued to investors on Tuesday, May 7th. HC Wainwright analyst A. Fein now expects that the company will earn ($0.66) per share for the quarter, down from their prior forecast of ($0.65). HC Wainwright currently has a "Buy" rating and a $20.00 target price on the stock. The consensus estimate for Foghorn Therapeutics' current full-year earnings is ($2.05) per share. HC Wainwright also issued estimates for Foghorn Therapeutics' Q4 2024 earnings at ($0.69) EPS, FY2024 earnings at ($2.56) EPS, FY2025 earnings at ($2.36) EPS, FY2026 earnings at ($2.28) EPS, FY2027 earnings at ($1.37) EPS and FY2028 earnings at ($0.34) EPS.
Foghorn Therapeutics (NASDAQ:FHTX - Get Free Report) last issued its quarterly earnings results on Thursday, March 7th. The company reported ($0.57) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.79) by $0.22. The business had revenue of $5.77 million for the quarter, compared to analysts' expectations of $4.91 million.
Separately, Wedbush reaffirmed an "outperform" rating and set a $13.00 target price on shares of Foghorn Therapeutics in a research note on Wednesday, April 10th.
Read Our Latest Research Report on FHTX
Foghorn Therapeutics Stock Down 0.7 %
Shares of FHTX stock traded down $0.04 during trading hours on Thursday, hitting $5.94. 82,536 shares of the company's stock were exchanged, compared to its average volume of 137,729. The firm has a 50 day moving average of $6.38 and a two-hundred day moving average of $5.35. Foghorn Therapeutics has a fifty-two week low of $2.70 and a fifty-two week high of $9.97. The firm has a market cap of $252.87 million, a P/E ratio of -2.59 and a beta of 3.15.
Institutional Trading of Foghorn Therapeutics
Several institutional investors have recently made changes to their positions in FHTX. Nisa Investment Advisors LLC lifted its stake in shares of Foghorn Therapeutics by 788.1% in the 4th quarter. Nisa Investment Advisors LLC now owns 5,000 shares of the company's stock valued at $32,000 after purchasing an additional 4,437 shares during the last quarter. State Board of Administration of Florida Retirement System purchased a new position in Foghorn Therapeutics during the first quarter worth about $77,000. Exchange Traded Concepts LLC boosted its stake in Foghorn Therapeutics by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 21,535 shares of the company's stock worth $139,000 after buying an additional 5,460 shares during the period. Alta Wealth Advisors LLC purchased a new stake in shares of Foghorn Therapeutics in the 4th quarter valued at approximately $194,000. Finally, Panagora Asset Management Inc. acquired a new position in shares of Foghorn Therapeutics in the 3rd quarter worth approximately $173,000. Hedge funds and other institutional investors own 61.55% of the company's stock.
Foghorn Therapeutics Company Profile
(
Get Free Report)
Foghorn Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.
Featured Articles
Before you consider Foghorn Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Foghorn Therapeutics wasn't on the list.
While Foghorn Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
